Xbrane Biopharma AB (XBRANE) AI Stock Analysis

• Market Cap: kr122.00M
• Dividend Yield: N/A
• Average Volume (3M): 117.17K
• Price to Earnings (P/E): 122.0
• Beta (1Y): 0.96
• Revenue Growth: 4.64%
• EPS Growth: N/A
• Country: SE
• Employees: 65
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.28
• Shares Outstanding: 20,605,349
• 10 Day Avg. Volume: 189,097
• 30 Day Avg. Volume: 117,165
• PEG Ratio: -1.22
• Price to Book (P/B): 27.69
• Price to Sales (P/S): 101.88
• P/FCF Ratio: -61.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -4.14
• Revenue Forecast (FY): kr186.50M

• Rating: 46 Neutral
• Price Target: kr6.50 ▼(-37.32% Downside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held down primarily by weak financial performance driven by ongoing operating losses and substantial negative operating/free cash flow, alongside a strong bearish technical trend with the price below all major moving averages. A strengthened 2025 balance sheet and a very low P/E provide some offset, but do not fully mitigate funding and execution risk implied by continued cash burn.

Positive Factors

Balance sheet improvement

The 2025 capital structure shows materially lower debt and much higher equity, reducing leverage and near-term refinancing pressure. A stronger balance sheet improves runway and bargaining power with partners, supporting program advancement and strategic optionality over coming quarters.

Partnership/licensing revenue model

Xbrane’s business model emphasizes out-licensing and partnerships that can deliver non-dilutive upfronts, milestones and royalties. This structure de-risks development spending, aligns incentives with commercial partners, and provides durable potential cash inflection points if programs progress.

In-house biologics development & manufacturing

Owning development and manufacturing capabilities is a structural competitive advantage in biosimilars: it supports tech transfer, lowers partner execution risk, enables contract services revenue, and can improve gross margins and partner attractiveness over the medium term.

Negative Factors

Persistent negative cash flow

Consistent and deep negative operating and free cash flows mean the company cannot self-fund development. Ongoing cash burn heightens dependence on external financing or partner payments, increasing dilution and execution risk for program advancement over the next several quarters.

Sustained operating losses

Operating results remain structurally loss-making, with negative EBIT/EBITDA across reported years. The 2025 positive net income appears driven by non-operating items, so core profitability has not been demonstrated, limiting ability to build internally funded growth.

Revenue volatility and recent decline

Revenue growth has been uneven and recently contracted materially, which increases forecasting uncertainty and weakens predictable milestone/royalty timing. This volatility complicates partner negotiations and heightens execution risk for sustaining development and commercialization plans.

Xbrane Biopharma AB Business Overview & Revenue Model

Company Description

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.

How the Company Makes Money

Xbrane Biopharma generates revenue primarily through the development and commercialization of its biosimilar products. The company's revenue model is centered on securing partnerships and licensing agreements with larger pharmaceutical firms, which may include upfront payments, milestone payments upon achieving development targets, and royalties on sales. Additionally, Xbrane may generate income through collaborations that facilitate the clinical development and regulatory approval of its biosimilar candidates. Significant partnerships with established players in the biopharmaceutical industry can enhance its market reach and provide financial backing, contributing to its overall earnings.

Xbrane Biopharma AB Financial Statement Overview

Summary

Balance sheet strength improved in 2025 with sharply lower debt and much higher equity, but core operations remain loss-making (negative EBIT/EBITDA) and revenue is volatile with a recent decline. Persistent and deep negative operating/free cash flow (2025 ~-251m) is the largest risk, and the 2025 net income appears driven by non-operating items rather than sustainable operating profitability.

Income Statement

Revenue has scaled materially versus earlier years, but growth has been volatile and most recently declined (2025 revenue down ~27% after a decline in 2024). Profitability remains weak on an operating basis, with negative EBIT and EBITDA in every year shown. A notable positive in 2025 is reported net income turning strongly positive despite operating losses, suggesting results were helped by non-operating items rather than core earnings power.

Balance Sheet

The balance sheet improved meaningfully in 2025, with debt falling sharply (from ~192m to ~58m) and equity rising substantially (from ~209m to ~561m), reducing leverage and strengthening the capital base. However, leverage had been elevated in 2023–2024 (debt-to-equity near ~1.35 in 2023 and ~0.92 in 2024), and returns on equity were deeply negative in those years, highlighting historical dependence on external financing and weak underlying profitability.

Cash Flow

Cash generation is the key weakness: operating cash flow and free cash flow are consistently negative across all years shown, and 2025 operating/free cash flow was deeply negative (~-251m). While free cash flow losses improved versus 2023 and 2022, the business has not demonstrated an ability to fund operations internally, increasing reliance on financing or balance-sheet resources despite the 2025 capital structure improvement.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	152.35M	198.70M	238.73M	57.62M	11.53M
Gross Profit	74.94M	180.47M	35.39M	41.04M	-684.00K
EBITDA	-16.50M	-181.97M	-282.03M	-149.34M	-167.59M
Net Income	127.24M	-266.22M	-388.17M	-172.23M	-191.01M
Balance Sheet
Total Assets	671.62M	842.43M	653.51M	690.51M	688.43M
Cash, Cash Equivalents and Short-Term Investments	86.59M	124.33M	65.40M	193.99M	295.18M
Total Debt	58.31M	191.72M	231.48M	38.22M	44.38M
Total Liabilities	110.97M	633.89M	482.17M	265.63M	256.69M
Stockholders Equity	560.65M	208.54M	171.34M	424.89M	431.74M
Cash Flow
Free Cash Flow	-250.69M	-185.97M	-423.45M	-254.04M	-296.96M
Operating Cash Flow	-250.69M	-133.73M	-406.68M	-193.92M	-219.61M
Investing Cash Flow	-37.14M	-52.25M	-16.77M	-60.13M	-77.35M
Financing Cash Flow	255.60M	243.62M	298.70M	148.86M	349.37M

Xbrane Biopharma AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Negative. The current price of 10.37 is above the 20-day moving average (MA) of 8.59, above the 50-day MA of 10.09, and below the 200-day MA of 22.19, indicating a bearish trend. The MACD of -1.32 indicates Positive momentum. The RSI at 22.41 is Positive, neither overbought nor oversold. The STOCH value of 4.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XBRANE.

Xbrane Biopharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRANE	46 Neutral	kr122.00M	121.99	-16.90%	―	4.64%	―
ACTI	45 Neutral	kr126.53M	-1.66	-1291.15%	―	―	28.54%
ACE	44 Neutral	kr364.11M	-6.44	-79.60%	―	―	31.62%
IVACC	44 Neutral	kr211.30M	-3.40	-25.66%	―	127.13%	56.91%
IMMU	43 Neutral	kr248.30M	-1.89	-16.51%	―	―	31.37%
GUARD	42 Neutral	kr32.27M	-0.24	-199.25%	―	―	0.30%

Xbrane Biopharma AB Corporate Events

Xbrane Swings to Profit as Ximluci Grows and Biosimilar Pipeline Advances

Xbrane Biopharma reported full-year 2025 revenue of SEK 152.4 million, with higher Ximluci product sales and license income contributing to a swing to a SEK 127.2 million profit from a large loss a year earlier, mainly driven by a gain from its Alvotech transaction. The company strengthened its balance sheet with an equity ratio of 83 percent, implemented a major share consolidation and capital reduction to clean up past losses, and opted against a dividend as it continues to prioritize R&D spending.

Operationally, Ximluci’s end-customer sales in Europe rose 63 percent in 2025, though Xbrane’s quarterly revenues remained volatile due to irregular deliveries to STADA and ongoing investments to lower production costs, expected to pay off from 2027. The firm is preparing to resubmit its ranibizumab biosimilar application to the FDA in March 2026 after addressing manufacturing observations cited in a Complete Response Letter, while advancing its Xdivane program with ongoing clinical recruitment and process scale-up ahead of a planned FDA filing in late 2027.

To bolster liquidity and flexibility, Xbrane entered into a conditional financing agreement with Fenja Capital II A/S, including a warrant issue linked to that facility. Management emphasizes that progress in its key development programs and forthcoming regulatory milestones are central to its strategy of consolidating its position in the global biosimilars market, with implications for future U.S. market entry and long-term growth prospects for shareholders and partners.

The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK10.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.

Xbrane Biopharma Sets February 20 Teleconference to Present 2025 Year-End Results

Xbrane Biopharma AB has scheduled a teleconference and webcast for investors, analysts and media on February 20, 2026, at 09:00 CET, to present its 2025 year-end report, which will be published an hour earlier that same morning. Chief executive Martin Åmark and chief financial officer and head of investor relations Jane Benyamin will lead the English-language presentation and subsequent Q&A, offering stakeholders a fresh look at the company’s financial performance and strategic progress following the European launch of its lead biosimilar Ximluci®.

The event underscores Xbrane’s efforts to maintain active engagement with the capital markets as it advances a biosimilar pipeline aimed at large reference markets and leverages its cost-efficient production platform. For shareholders and potential investors, the year-end briefing will be a key opportunity to assess how the company is executing on its growth strategy in the competitive biosimilars landscape and how its commercial rollout and pipeline developments may support future value creation.

The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK10.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.